ArticleJHEP reports : innovation in hepatology2025
Blood and tissue dysregulated bile acids and short-chain fatty acids in cholangiocarcinoma.
Article in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bile acid signaling in health and disease.Molecular biomedicine · 2026Review
- Microbial dysbiosis in cholangiocarcinoma.Frontiers in microbiology · 2026Review
- Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment.Frontiers in immunology · 2025Review
- Multi-Omics Biomarker Signatures for Precision Diagnosis and Prognosis in Primary Liver Cancer: A Literature Review.BioFactors (Oxford, England)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background & Aims: Dysregulated bile acid (BA) homeostasis has been implicated in the initiation and progression of cholangiocarcinoma (CCA). The aim of this study was to investigate the roles of circulating and tumor BAs, oxysterols, short-chain fatty acids (SCFAs), transcriptomic changes, and stool microbiota composition in CCA, and their potential diagnostic and therapeutic implications. Methods: We used ultra-performance liquid chromatography-tandem mass spectrometry to quantify BAs, oxysterols, and SCFAs in serum from patients with benign focal nodular hyperplasia (n = 27), primary sclerosing cholangitis (PSC; n = 20), intrahepatic CCA (iCCA; n = 29), and extrahepatic CCA (eCCA; n = 35), and in tumor and adjacent non-tumor iCCA (n = 30) and eCCA (n = 26) tissues. Publicly available liver transcriptome and gut microbiome datasets were analyzed to assess BA metabolic pathway activity and related gene expression profiles. Results: Total primary conjugated BA levels and the taurine-to-glycine ratio of conjugated BAs were significantly elevated in the serum of patients with PSC and CCA compared to controls with focal nodular hyperplasia ( Conclusions: Profound alterations in serum and tissue levels of primary and taurine-conjugated BAs occur during cholangiocarcinogenesis. Further elucidation of the mechanisms regulating BA and oxysterol metabolism in CCA may offer new avenues for diagnosis and therapy. Impact and implications: Cholangiocarcinomas (CCAs) are aggressive malignancies with limited therapeutic options. Although CCA cells exhibit distinct metabolic profiles, investigating their regulation through the enterohepatic axis remains challenging. In this study, targeted metabolomics was used to analyze bile acid (BA) profiles in serum and liver tissue, serum short-chain fatty acids, and hepatic oxysterol levels in patients with intrahepatic and extrahepatic CCA, compared to controls with focal nodular hyperplasia and primary sclerosing cholangitis. Liver transcriptome analysis revealed differentially expressed genes involved in BA metabolism in patients with primary sclerosing cholangitis and CCA. Correlations were also examined between BAs, oxysterols, short-chain fatty acids, clinical features, and microbiome components implicated in CCA development. These findings provide new insights into BA dysregulation in CCA and establish a foundation for the development of novel diagnostic biomarkers and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.